Bortezomib (PS-341)

Catalog No.S1013

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bortezomib (PS-341) Chemical Structure

Bortezomib (PS-341) Chemical Structure
Molecular Weight: 384.24

Validation & Quality Control

Cited by 142 publications:

20 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets 20S proteasome [1]
(Cell-free assay)
IC50 0.6 nM(Ki)
In vitro Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MCF-7MmPoR5l1d3SxeHnjJGF{e2G7MWK1NEDPxE1?NInzd5E1QCCqMoflSG1UVw>?MX\LbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUmlM4PVTFExPDl7NkSz
OVCA 429NH\P[olHfW6ldHnvckBCe3OjeR?=NFvydXU{ODBibl2=M13zOFQ5KGh?NUjmb49pTE2VTx?=NVL5NXczTGm|coXweJMhcW62YXP0JI12dHSrY3XscJVt[XJidIXtc5Ihe3CqZYLvbYR{MoHGNVA6QTl5Nk[=
RPMI8226Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF35[GkyODBibl2=Mk\JOFghcA>?M2KxUmROW09?M2\SdmlEPTB;M{Cgcm0>MUGxNVMxPjR6OR?=
Dox40M2HKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{m3eFExOCCwTR?=MXW0PEBpM2\FW2ROW09?MUPJR|UxRTRyIH7NNHXHdFIyOTNyNkS4PS=>
MR20MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHraW4cyODBibl2=NU[wNItpPDhiaB?=NILPcI1FVVORMYPJR|UxRTJyIH7NMlHXNVE{ODZ2OEm=
LR5MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHvZ4QyODBibl2=M4PNTFQ5KGh?M17xbWROW09?M{LSVWlEPTB;MkCgcm0>Mlr5NVE{ODZ2OEm=
U266NUDNSoQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2G5TVExOCCwTR?=MkDROFghcA>?NIDoVY1FVVORNIDmTGRKSzVyPUOgcm0>MYOxNVMxPjR6OR?=
IM-9NYHnR2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;Wc2MyODBibl2=NI\ldow1QCCqMWPEUXNQMYrJR|UxRTZibl2=MYOxNVMxPjR6OR?=
Hs SultanMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnraNVAxKG6PNEDHVWs1QCCqMojnSG1UVw>?M{\DRWlEPTB;MkCgcm0>NFLlflQyOTNyNkS4PS=>
PAM-LY2NYqyfm1pTnWwY4Tpc44hSXO|YYm=M2jndlExOCCwTR?=NIHyPIsyOiCqM2K5b2ROW09?NWSwWXJ5UW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44>M33uT|EyOzVyOUGz
PAM 212MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvHfINPOTByIH7NM3ryW|czKGh?M1rMcWROW09?NHXMXnJKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=M1P0UlEyOzVyOUGz
PAM-LY2MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfo[5RsOTByIH7NNU\uUWZNPzJiaB?=NX\STlRoTE2VTx?=M{S0bmlvcGmkaYTzJINmdGxidnnhZoltcXS7M3zIfVEyOzVyOUGz
B4B8MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXKxNFAhdk1?MXm3NkBpMV3EUXNQMmHnTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?NVHsU5VMOTF|NUC5NVM>
B7E3MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYSzbmxtOTByIH7NM{[2WlczKGh?MXvEUXNQNGDWSFFKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=NVzjPHpbOTF|NUC5NVM>
UM-SCC-9NYfZdld2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLTZZQ{OTByIH7NMYC3NkBpNE\PeWdFVVORNYDzb3ZuUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=NIfYSZAyOTN3MEmxNy=>
UM-SCC-11BMk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUixNFAhdk1?M4LDU|czKGh?NIn0d49FVVORNVm2[2FyUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=NWHEeGxtOTF|NUC5NVM>
H460MVzGeY5kfGmxbjDBd5NigQ>?NGW0TpEyOCEQvF2=NYe1TpRWOjRiaB?=MUDEUXNQNWL4SYllUW6mdXPld{BD[2xvMjDwbI9{eGixconsZZRqd25iYX7kJINt\WG4YXflJINwenKnbHH0[YQhf2m2aDDHNk1OKHCqYYPlJIFzemW|dB?=NWnDZoNYOTJ2OUKxNVc>
U266NYrtdGZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUm1NFAhdmdxbXy=MlXZOFghcA>?MmLFSG1UVw>?M3WwdWlvcGmkaYTzJINmdGxiZ4Lve5RpMV6xNlY{OTZzOR?=
ARH77MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTLOVAxKG6pL33sNVrNXmp[PDhiaB?=MWTEUXNQMVvJcohq[mm2czDj[YxtKGe{b4f0bC=>MnnINVI3OzF4MUm=
WAD-1M3fu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37hXVUxOCCwZz;tcC=>MVu0PEBpMXLEUXNQMV\Jcohq[mm2czDj[YxtKGe{b4f0bC=>NV\ZXmRqOTJ4M{G2NVk>
U266/LR7M{XGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU[1NFAhdmdxbXy=MlXPOFghcA>?MmTtSG1UVw>?MUDJcohq[mm2czDj[YxtKGe{b4f0bC=>NUXCWohuOTJ4M{G2NVk>
U266/dox4M4TYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HtOVUxOCCwZz;tcC=>MnrmOFghcA>?NELpS3NFVVORMVfJcohq[mm2czDj[YxtKGe{b4f0bC=>Mlz2NVI3OzF4MUm=
RPMI8226/LR5MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzob5Q2ODBibnevcYw>M2rJO|Q5KGh?M1vB[WROW09?NGDIXpZKdmirYnn0d{Bk\WyuIHfyc5d1cA>?MXixNlY{OTZzOR?=
H460NUPtc3J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX6xNEDPxE1?NE\Td5M4OiCqM{XPeWROW09?NYnOflk1UUN3ME2xNFAhdk1?MUKxNlY{OTZ{MB?=
H358NYCzZlRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17XR|ExKM7:TR?=Ml;ZO|IhcA>?MVnEUXNQNVjBdGNtUUN3ME23NEBvVQ>?NWi3R|A1OTJ4M{G2NlA>
H322MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUL4Zmp3OTBizszNM4fHSlczKGh?M3zLeWROW09?MkL1TWM2OD14MkCgcm0>NGXte4IyOjZ|MU[yNC=>
H460MYHGeY5kfGmxbjDBd5NigQ>?NWPRVXFDOTByIH7NM{Dab|I1KGh?NIjQOWdFVVORNV\Ge3NWUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?=M3PSclEzPjNzNkKw
LNCap-Pro5MWTGeY5kfGmxbjDBd5NigQ>?MWexJO69VQ>?M136UFQhcA>?M2\nfmROW09?M{fYXHN1[WKrbHn6[ZMheDV|NF7BW5EyPDZzMkWzNi=>
T29NFrtXZpCeG:ydH;zbZMhSXO|YYm=M3fG[FUxKG6PMnPPOFghcCB?NYXzWY9ITE2VTx?=MmewTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?NHLvdmMyPjd5OEG3PS=>
T29Kt1NF7JR21CeG:ydH;zbZMhSXO|YYm=M{ThSVUxKG6PNVrYXIo5PDhiaDC=M37hV2ROW09?M1;vSmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?Mo[5NVY4PzhzN{m=
HCT116NV[2OnRtSXCxcITvd4l{KEG|c3H5NYHKOJJ[PTBibl2=MWS0PEBpKA>?MnTmSG1UVw>?MnPVTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?MWCxOlc4QDF5OR?=
HKe-3NUO1NmRMSXCxcITvd4l{KEG|c3H5M1nkNFUxKG6PNGP5WWI1QCCqIB?=NFfhVVRFVVORMnPoTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?NILpPYkyPjd5OEG3PS=>
NB-1691NYWwW5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWS1e2h2OSEQvF2=NHvRSm44OiCqM3\sN2lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?=M1\LPFE4Pjh7Nki0
CHLA-255MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoT1NUDPxE1?NVjXeFNRPzJiaB?=NV\LR4d1UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKlNFL5[YEyPzZ6OU[4OC=>
SK-N-ASM4ntRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXmxJO69VQ>?M3fMd|czKGh?MW\Jcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBnMYexO|Y5QTZ6NB?=
NB-1691NG\IVJlHfW6ldHnvckBCe3OjeR?=MnTaNVAhdk1?M4XYNFI1KGh?MVLTbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPlNEi1[XIyPzZ6OU[4OC=>
CHLA-255MmPuSpVv[3Srb36gRZN{[Xl?MoLYNVAhdk1?MUOyOEBpNX;DWXFFVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W=M3i2Z|E4Pjh7Nki0
RPMI 8226MX;GeY5kfGmxbjDBd5NigQ>?MYKyNEBvVQ>?MU[4JIg>NXnWWIRsW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?M4q5OFE6PDN4MEWw
MM.1SMkPxSpVv[3Srb36gRZN{[Xl?MYmyNEBvVQ>?NIjSZYI5KGh?NV\W[YRoW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?Mny0NVk1OzZyNUC=
U266NHrkWJNHfW6ldHnvckBCe3OjeR?=NXGwe45bOjBibl2=NFTrS4c5KGh?NHXxZ45UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>?M2nXT|E6PDN4MEWw
OPM1NUPkVJh1TnWwY4Tpc44hSXO|YYm=MoT0NlAhdk1?MWe4JIg>MUHTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>NXm4eWhPOTl2M{[wOVA>
INA6Mk\SSpVv[3Srb36gRZN{[Xl?NFfs[ZYzOCCwTR?=M{LsUVghcA>?NXHN[ldwW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?MkjyNVk1OzZyNUC=
OPM2NGi5d5hHfW6ldHnvckBCe3OjeR?=M1HpRVIxKG6PNGrsWGw5KGh?NHXtNpVUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>?MmKzNVk1OzZyNUC=
RPMI 8226NGXt[FRHfW6ldHnvckBCe3OjeR?=MXGyNEBvVQ>?M4jEdlghcA>?NUXLNoZFUW6mdXPld{BFVkFic4nueIhme2m|NEW2UWcyQTR|NkC1NC=>
BaF/3MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVH5[4k6OTByIH7NM3r6UFQ5KGh?MXTJR|UxRTZwMjDuUS=>M{\BWFIxOzB3Nkmy
BaF/3-p210MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGS1SGMyODBibl2=M3y3TlQ5KGh?NUTQVJV{UUN3ME20Mlchdk1?MkPBNlA{ODV4OUK=
TCC-SNWLTVnFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzPV41uOTByIH7NMlvwOFghcA>?MnSyTWM2OD1{Lkigcm0>NF76WIQzODNyNU[5Ni=>
BaF/3NVzCWW1xTnWwY4Tpc44hSXO|YYm=NXnjSHJUPiCwTR?=Mny5OFghcA>?NEHwSmpKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q>NF7UfXozODNyNU[5Ni=>
BaF/3-p210NVOzcGVOTnWwY4Tpc44hSXO|YYm=MnOxOkBvVQ>?NXvZbnVQPDhiaB?=NEfMRYFKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1MnjRNlA{ODV4OUK=
BaF/3-p210MWfGeY5kfGmxbjDBd5NigQ>?M4rmflYhdk1?M1HtWVI1KGh?MnnFVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ?NESxWWMzODNyNU[5Ni=>
RajiNXnIO5VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUGxJO69VQ>?MWqyOEBpM4PSV3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=NF3oNHkzOTF5MEm4PC=>
LCL-1M3fCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PCN|Eh|ryPM1jnWVI1KGh?NG\rbWtT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=NY\Ee4dvOjFzN{C5PFg>
LCL-2NXHYOJFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3zeYVUOSEQvF2=NIrFdZczPCCqNFi3e2xT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=MXWyNVE4ODl6OB?=
BJABNXTrfVBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7WNUDPxE1?M2r6TFI1KGh?MXvS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?MYqyNVE4ODl6OB?=
SNT-13MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\6cVEh|ryPMXKyOEBpMmnTVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLiMV6yNVE4ODl6OB?=
SNT-16NW\ZXno2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\XNUDPxE1?NVrBXY55OjRiaB?=MUPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?MVWyNVE4ODl6OB?=
JurkatMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjaXph[OSEQvF2=Ml3WNlQhcA>?MUnS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?NXvMTpZ[OjFzN{C5PFg>
KAI-3NEHXb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLrNUDPxE1?NVvu[FBtOjRiaB?=M3LvbHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=M1iwUVIyOTdyOUi4
SNK-6MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU[xJO69VQ>?NWK2N|dUOjRiaB?=M1S2ZXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=MVuyNVE4ODl6OB?=
KHYG-1MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4G0WVEh|ryPM4jmflI1KGh?M136cnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=MmHpNlEyPzB7OEi=
SNT-16MU\BdI9xfG:|aYOgRZN{[Xl?NIjLRpMyKM7:TR?=M2j4OFYhcA>?MYjJcoR2[2W|IHPlcIwh[XCxcITvd4l{M3nyOVIyOTdyOUi4
JurkatNFvpOXVCeG:ydH;zbZMhSXO|YYm=MYKxJO69VQ>?M1[3[FYhcA>?NIHDc|JKdmS3Y3XzJINmdGxiYYDvdJRwe2m|Mle3NlEyPzB7OEi=
KAI-3MUDBdI9xfG:|aYOgRZN{[Xl?MYCxJO69VQ>?MnrROkBpMkXFTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?MVqyNVE4ODl6OB?=
KHYG-1NH;nPW1CeG:ydH;zbZMhSXO|YYm=NXXMRnZ{OSEQvF2=NEXDfYo3KGh?NV;2N4drUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=MmDBNlEyPzB7OEi=
SNT-13MYLBcpRqfmm{YXygRZN{[Xl?NEHNOYMyKM7:TR?=NGnPPHAzPCCqNH\GSFRKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?M{fXUlIyOTdyOUi4
SNT-16MofQRY51cX[rcnHsJGF{e2G7MkG4NUDPxE1?M37C[VI1KGh?MoXDTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJXNXrYdIozOjFzN{C5PFg>
KAI-3NH:zR5pCdnSrdnnyZYwhSXO|YYm=M17DOlEh|ryPMXSyOEBpNXfRXXc5UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKYMl7sNlEyPzB7OEi=
SNK-6MXzBcpRqfmm{YXygRZN{[Xl?NGXPWZIyKM7:TR?=MkTpNlQhcA>?MkXITY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJXM{DC[|IyOTdyOUi4
RAW 264.7MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVexNFAhdk1?NVjscJRMPDhiaB?=Mn;ZVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLiM4m1XlIzPDJ5MUW0
A375M3vlfmFxd3C2b4Ppd{BCe3OjeR?=NXKxcW46OTBibl2=NHmzNVAzPCCqNWjVOWF4UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=MkDmNlMxPzlyOEO=
BLMM1PTSGFxd3C2b4Ppd{BCe3OjeR?=NX\mSG9FOTBibl2=M2OwO|I1KGh?MYPJcoR2[2W|IHPlcIwh[XCxcITvd4l{MUeyN|A4QTB6Mx?=
A375NGfhWnZCfXSxcHjh[5khSXO|YYm=M1rjSFExKG6PM2K0bFEzKGh?NGTPOVhKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=>NFTsN5czOzB5OUC4Ny=>
BLMMX7BeZRweGijZ4mgRZN{[Xl?NX:3[2FzOTBibl2=NF7wbVEyOiCqM{fHfmlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXzMVuyN|A4QTB6Mx?=
H1299NVnZR4lxSXCxcITvd4l{KEG|c3H5MlfFPFAhdk1?M1jTNVI1KGh?MnHsSG1UVw>?MYDT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>?NInCZ4kzPTN{M{[5Ny=>
Hut-78NWfKZoJzTnWwY4Tpc44hSXO|YYm=M3XEb|ExOCCwTR?=M4P2dVI1KGh?M1voZmROW09?NXjUb3BsTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMDDlfJBz\XO|aX;uMoHVNlU3QDF|M{W=
H9MVLGeY5kfGmxbjDBd5NigQ>?MoTFNVAxKG6PMVOyOEBpM4\vcGROW09?MmHhSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:wMlnaNlU3QDF|M{W=
HHMoTaSpVv[3Srb36gRZN{[Xl?MmD6NVAxKG6PMVOyOEBpMn7vSG1UVw>?M{Dy[YRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?=MWiyOVY5OTN|NR?=
Hut-78M2PpZW1q\3KjdHnvckBCe3OjeR?=MXuxNFAhdk1?NV3NOWtlOjRiaB?=M3nhc2ROW09?MXfS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBnNIPmSXEzPTZ6MUOzOS=>
HHM{Ttem1q\3KjdHnvckBCe3OjeR?=NUnRWYNmOTByIH7NNVXXN5dSOjRiaB?=MXfEUXNQMUTS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTFnMoS4NlU3QDF|M{W=
U937MWHGeY5kfGmxbjDBd5NigQ>?NUWw[VJPOTByIH7NNYnxb4U5PiCqM1XFdWlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN?M3PWR|I2PzlzNEe3
human PBMCM3q4PGZ2dmO2aX;uJGF{e2G7MYGxNFAhdk1?MmP6NlQhcA>?NYrh[5BjUW6mdXPld{BKVC16IILlcIVie2V?MnXxNlU4QTF2N{e=
ES6MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTqZ2ZKSzVyPUCuNFAzOSCwTR?=MWjTRW5ITVJ?
SK-UT-1NVLwOGhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXQTWM2OD1yLkG2N{BvVQ>?NX76VG9oW0GQR1XS
SH-4M1fPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnBUXhEUUN3ME2wMlE4OyCwTR?=MWDTRW5ITVJ?
TE-9MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjKTWM2OD1yLkG4NkBvVQ>?M4KwV3NCVkeHUh?=
A253MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHkZXpKSzVyPUCuNlA5KG6PNEHZc4ZUSU6JRWK=
no-10NIrtO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf4RotKSzVyPUCuNlEhdk1?NETtOndUSU6JRWK=
MMAC-SFMnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYe3ZYlxUUN3ME2wMlIyPiCwTR?=NWHJOm5mW0GQR1XS
A101DMmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrscWZqUUN3ME2wMlIzPSCwTR?=NHnGe5RUSU6JRWK=
NTERA-S-cl-D1MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHGTWM2OD1yLkK0N{BvVQ>?MUDTRW5ITVJ?
8-MG-BAM3ztWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jhNWlEPTB;MD6yOUBvVQ>?M1fqVHNCVkeHUh?=
KNS-42MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrsVGlCUUN3ME2wMlI2QCCwTR?=MnHvV2FPT0WU
LXF-289NXK5WXUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXryU3E2UUN3ME2wMlI3QSCwTR?=MorlV2FPT0WU
OVCAR-4NUD1R3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4r2ZWlEPTB;MD6yPFkhdk1?MYLTRW5ITVJ?
LOUCYNIfiVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2q2eGlEPTB;MD6yPVMhdk1?NHf2UGxUSU6JRWK=
BB65-RCCM33yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTBwM{C0JI5ONEPLOW1USU6JRWK=
D-542MGNYLhfJNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPpOZFKSzVyPUCuN|I6KG6PNVPvXJhCW0GQR1XS
ONS-76NIrPT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Xq[2lEPTB;MD6zN{BvVQ>?NIjOV2dUSU6JRWK=
BB30-HNCNFz3OVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXm0TGlmUUN3ME2wMlM{PSCwTR?=MoXhV2FPT0WU
KS-1NX;VcJdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVezb4hzUUN3ME2wMlM1KG6PMlHwV2FPT0WU
A388NX;pb|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTBwM{W2JI5OM4LKUHNCVkeHUh?=
ES8M1KzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWP6OnlnUUN3ME2wMlQhdk1?M{PoVXNCVkeHUh?=
MZ2-MELNVrvOFhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PsWmlEPTB;MD60NFchdk1?MkXKV2FPT0WU
HCC2998NGXiXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2ryO2lEPTB;MD60NVIhdk1?MWTTRW5ITVJ?
D-247MGNHzqd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmSzTWM2OD1yLkSxN{BvVQ>?MXXTRW5ITVJ?
ACNNV[2S2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPsTWM2OD1yLkSxO{BvVQ>?NXq4Z3A1W0GQR1XS
LB2518-MELMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPYTWM2OD1yLkSyOUBvVQ>?NGTrT|lUSU6JRWK=
ES1NXO0VFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\mTWM2OD1yLkSzJI5ONEjuSWFUSU6JRWK=
HCE-TNXXVTZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvKWnVKSzVyPUCuOFM6KG6PM2TxfnNCVkeHUh?=
OS-RC-2M{Hm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX23bnl3UUN3ME2wMlQ1KG6PMUfTRW5ITVJ?
MFH-inoMkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTBwNESzJI5ONXT6UYduW0GQR1XS
OCUB-MM3O0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnsNIhKSzVyPUCuOFQ4KG6PNEXiVmtUSU6JRWK=
CP66-MELMn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTBwNEezJI5OMWPTRW5ITVJ?
LB771-HNCNYPBbJpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIe4O2FKSzVyPUCuOFc1KG6PNWrnbHJRW0GQR1XS
DSH1NH;tbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfVXWhKSzVyPUCuOFghdk1?MkK3V2FPT0WU
HUTU-80MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTSbYFKSzVyPUCuOVM{KG6PNH:zWWdUSU6JRWK=
CESSM1ex[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzDTWM2OD1yLkWzPEBvVQ>?MU\TRW5ITVJ?
NCI-H747Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHq1UFVKSzVyPUCuOVM6KG6PM1zwTHNCVkeHUh?=
HT-144NGr6NIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwNUe2JI5ONWPhcHhrW0GQR1XS
COLO-829NVHZ[YZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XHT2lEPTB;MD62NVQhdk1?M2KzVnNCVkeHUh?=
A4-FukNF\EfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTBwNkKzJI5ONVPucXJbW0GQR1XS
GI-ME-NMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7UW2tKSzVyPUCuOlM1KG6PMkHlV2FPT0WU
LB831-BLCMmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfucmhqUUN3ME2wMlY1OSCwTR?=M3XXfHNCVkeHUh?=
HOP-62NED0PXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTBwNkS3JI5OM1jaUXNCVkeHUh?=
BB49-HNCMoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHWzXmFKSzVyPUCuOlUzKG6PMXvTRW5ITVJ?
D-336MGNXfuU4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHtZYlKSzVyPUCuOlU4KG6PNWfnUlV3W0GQR1XS
TK10MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTBwNke5JI5OMkjEV2FPT0WU
Ramos-2G6-4C10M4jTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTBwNkmzJI5OM{DtT3NCVkeHUh?=
LB373-MEL-DMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwNzDuUS=>M4HRdnNCVkeHUh?=
SF126NF\vcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofSTWM2OD1yLkewNUBvVQ>?MnjjV2FPT0WU
UACC-257MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nYSGlEPTB;MD63NUBvVQ>?NUSyfWY1W0GQR1XS
KINGS-1Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTBwN{KyJI5OMk[1V2FPT0WU
LS-513MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFW0WJhKSzVyPUCuO|M6KG6PM4XZNHNCVkeHUh?=
GI-1Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUG3b5ZMUUN3ME2wMlc3PCCwTR?=NEPwbndUSU6JRWK=
ES7MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;Se2w{UUN3ME2wMlc3PiCwTR?=MYTTRW5ITVJ?
LB2241-RCCMkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTBwOEC0JI5OM3HYcnNCVkeHUh?=
D-263MGMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37D[WlEPTB;MD64NFchdk1?MVPTRW5ITVJ?
SW684MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTBwOEKxJI5OM3voXXNCVkeHUh?=
ML-2MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEGyToRKSzVyPUCuPFIyKG6PMm\jV2FPT0WU
SK-LMS-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTqTWM2OD1yLki1OEBvVQ>?MYLTRW5ITVJ?
TE-5MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVuwc2N3UUN3ME2wMlg3PSCwTR?=M2G1Z3NCVkeHUh?=
QIMR-WILNFHiWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV35S4l[UUN3ME2wMlg5QSCwTR?=MlXTV2FPT0WU
NCI-H1355NHXTR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnH2TWM2OD1yLki5OUBvVQ>?MlS1V2FPT0WU
SNB75MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLkTWM2OD1yLkmxNkBvVQ>?MofGV2FPT0WU
RXF393M2nKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYWxNlNWUUN3ME2wMlkyPCCwTR?=NV32VJZHW0GQR1XS
IST-MEL1NV\Gc2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX5bGhKSzVyPUCuPVE4KG6PM1zjZnNCVkeHUh?=
SF268NF;oNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2T5SmlEPTB;MD65NlMhdk1?NFfFTXJUSU6JRWK=
KALS-1NYX5TnNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3r2OmlEPTB;MD65NlUhdk1?MWnTRW5ITVJ?
HC-1MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYiwR2JSUUN3ME2wMlk4PSCwTR?=MWnTRW5ITVJ?
SW872MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPj[5NKSzVyPUCuPVk3KG6PMXfTRW5ITVJ?
PSN1NFTaeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnWfZNKSzVyPUGuNFEhdk1?MWnTRW5ITVJ?
TE-1NHjSTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTFwMEOgcm0>NWfiSZlZW0GQR1XS
TE-10Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHwe4VLUUN3ME2xMlA{KG6PMX7TRW5ITVJ?
RKONV;wTI5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4D0XWlEPTB;MT6wOkBvVQ>?NWDhXmZ7W0GQR1XS
LC-2-adMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPOTWM2OD1zLkC4JI5ONUi2SndlW0GQR1XS
SK-MM-2NYHHZYp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFwMEmgcm0>NI\Sc2FUSU6JRWK=
VA-ES-BJMnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTFwMEmgcm0>M{\kbHNCVkeHUh?=
MZ7-melM1XsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\mUWlEPTB;MT6wPUBvVQ>?Ml72V2FPT0WU
D-392MGNFqybZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTFwMTDuUS=>NXTQZmNRW0GQR1XS
CCRF-CEMNV;6dppvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XYXmlEPTB;MT6xN{BvVQ>?M{LqcXNCVkeHUh?=
EM-2NXezN3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1ziRWlEPTB;MT6xOkBvVQ>?M1nP[nNCVkeHUh?=
HAL-01NHHxdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoqyTWM2OD1zLkG4JI5ONV3HbpNNW0GQR1XS
TE-8NWTZcVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFwMUmgcm0>MWXTRW5ITVJ?
NCI-H1882MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTJTWM2OD1zLkKgcm0>M4\rRnNCVkeHUh?=
DaudiNVyySpl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;FTWM2OD1zLkKyJI5OMn3FV2FPT0WU
BL-41MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfNTWM2OD1zLkK1JI5ONV\jbZl5W0GQR1XS
SRM1jyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTFwMkWgcm0>M2fDNXNCVkeHUh?=
KM12M3vBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTUe5lWUUN3ME2xMlI4KG6PNH;uS4dUSU6JRWK=
K5MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnjO3dsUUN3ME2xMlI5KG6PNUD6[YROW0GQR1XS
A3-KAWNInyXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkH2TWM2OD1zLkK4JI5ONHSwWIRUSU6JRWK=
CMKM135SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7LdmZ5UUN3ME2xMlI6KG6PNFTHOHlUSU6JRWK=
Calu-6M4LOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIi2R4xKSzVyPUGuNlkhdk1?MXLTRW5ITVJ?
IST-SL2NYDKZ4VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTFwM{Ggcm0>NGDEb2RUSU6JRWK=
OPM-2MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjscJdKSzVyPUGuN|Mhdk1?MYLTRW5ITVJ?
DU-4475MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjRTWM2OD1zLkO2JI5OMnjaV2FPT0WU
ECC12MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFS4Z5ZKSzVyPUGuN|chdk1?MVTTRW5ITVJ?
L-540NHTpfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1W2UGlEPTB;MT6zO{BvVQ>?MojXV2FPT0WU
CAS-1NXLqOIhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXLTWM2OD1zLkO3JI5OMXHTRW5ITVJ?
PF-382MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLlOG82UUN3ME2xMlQ4KG6PNUDvbG1tW0GQR1XS
LS-411NMnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTFwNUOgcm0>NWrJe5lHW0GQR1XS
NCI-H69MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfiTWM2OD1zLkW0JI5ONIfrXGlUSU6JRWK=
NB12M1rIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofPTWM2OD1zLkW2JI5ONF\qW25USU6JRWK=
HELMn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfG[HhRUUN3ME2xMlYyKG6PMn\2V2FPT0WU
GCIYMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTFwNkKgcm0>NXfmPWdCW0GQR1XS
EHEBNHrkVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojxTWM2OD1zLk[3JI5OM2XlPHNCVkeHUh?=
TGBC1TKBM3z4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HOcGlEPTB;MT63NUBvVQ>?MUnTRW5ITVJ?
KURAMOCHIMmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTFwN{Kgcm0>NF;k[pBUSU6JRWK=
U-266NUTBb3hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{njd2lEPTB;MT63OkBvVQ>?MVjTRW5ITVJ?
LC4-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDITWM2OD1zLke5JI5ONGrYbZBUSU6JRWK=
NCI-H2126NWPDdlVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTFwODDuUS=>M1LEO3NCVkeHUh?=
NCI-H1092M3vYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\CV2lEPTB;MT64JI5OMVzTRW5ITVJ?
GB-1NFjTPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3y5WmlEPTB;MT64NUBvVQ>?NVvJfVhFW0GQR1XS
MV-4-11NGnzTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLPTWM2OD1zLkiyJI5ONIH5b|dUSU6JRWK=
BeckerM3y1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFwOEOgcm0>NHjXcFlUSU6JRWK=
MPP-89M37oTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojzTWM2OD1zLki5JI5OMV7TRW5ITVJ?
BE-13MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzp[G1KSzVyPUGuPVMhdk1?NVX2U|lHW0GQR1XS
697MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTFwOUmgcm0>M{XPVXNCVkeHUh?=
NKM-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDNTWM2OD1{IH7NMWPTRW5ITVJ?
NB13MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHiwcoJKSzVyPUKgcm0>NH\XPWZUSU6JRWK=
LS-123NWLuSpExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPKZWI2UUN3ME2yMlAzKG6PNGTYSnRUSU6JRWK=
NB17MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTJwMESgcm0>MVTTRW5ITVJ?
LAN-6NW\SeGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWj2bZhiUUN3ME2yMlA2KG6PNEPpPGlUSU6JRWK=
EW-24NHO4UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDqTWM2OD1{LkC4JI5OMV7TRW5ITVJ?
NOS-1NYW4NGQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPQ[JZjUUN3ME2yMlEyKG6PM1KzTnNCVkeHUh?=
BL-70M3OyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\zTWM2OD1{LkGyJI5ONUX0OolXW0GQR1XS
GT3TKBNF[wOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUixOXZLUUN3ME2yMlEzKG6PNFewNmRUSU6JRWK=
HHNF\Rc|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDUV4xKSzVyPUKuNVMhdk1?MX7TRW5ITVJ?
KE-37MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzLWG4zUUN3ME2yMlE{KG6PMUnTRW5ITVJ?
MOLT-4M37yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nQb2lEPTB;Mj6xN{BvVQ>?MnPlV2FPT0WU
EKVXM2PCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHq3b2dKSzVyPUKuNVQhdk1?MVnTRW5ITVJ?
KGNNGnNXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjobXlKSzVyPUKuNVUhdk1?M1\UNnNCVkeHUh?=
ES4NInGd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[4O2lEPTB;Mj6xOkBvVQ>?MVTTRW5ITVJ?
SJSA-1NIW2cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofSTWM2OD1{LkKxJI5OM3u5WXNCVkeHUh?=
KMOE-2M2XodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIW5VIhKSzVyPUKuNlMhdk1?MWDTRW5ITVJ?
NB5NICzW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTJwMkegcm0>M4Pw[nNCVkeHUh?=
BC-1NYm3doE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DvemlEPTB;Mj6zNUBvVQ>?NE\xVnFUSU6JRWK=
NB10MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHMcGFKSzVyPUKuN|Ihdk1?MX\TRW5ITVJ?
RPMI-8226NXGyW5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTJwM{Wgcm0>NEXG[GxUSU6JRWK=
SCC-3NVLzc4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTJwM{egcm0>M{e5d3NCVkeHUh?=
ARH-77NUK4RlhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn2xTWM2OD1{LkO4JI5ONFPIfZdUSU6JRWK=
NCI-H748Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnHTWM2OD1{LkO5JI5ONVLVTYl1W0GQR1XS
KU812NYfEPYhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnpbJB6UUN3ME2yMlQzKG6PNIDPN4ZUSU6JRWK=
NCI-H64NEPMXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPETWM2OD1{LkS0JI5OMmfxV2FPT0WU
NB69MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJwNE[gcm0>Mlf4V2FPT0WU
KNS-81-FDM1zIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvKTWM2OD1{LkS4JI5OMUDTRW5ITVJ?
LB1047-RCCMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnX0TWM2OD1{LkW3JI5OMXvTRW5ITVJ?
EB-3NFfsXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3O4WGlEPTB;Mj62OkBvVQ>?M{XtU3NCVkeHUh?=
Mo-TM1LEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvwdWVGUUN3ME2yMlc1KG6PMmH3V2FPT0WU
EW-16MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDL[olKSzVyPUKuO|Uhdk1?NYHz[VVrW0GQR1XS
CTV-1MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTJwODDuUS=>NUXvUFJvW0GQR1XS
ETK-1NIjycW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVX2fVF1UUN3ME2yMlg1KG6PMoW2V2FPT0WU
C2BBe1NUnYW2NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTJwOEmgcm0>MU\TRW5ITVJ?
MOLT-16MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;rSXVPUUN3ME2yMlg6KG6PNWrrSVd3W0GQR1XS
SW954MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTJwOTDuUS=>NWLsVnUxW0GQR1XS
HTM3\weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3f0VGlEPTB;Mz6wNkBvVQ>?MWnTRW5ITVJ?
KARPAS-299MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzPOFhKSzVyPUOuNFYhdk1?NHn6SY1USU6JRWK=
MONO-MAC-6NX7ocmhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M130cGlEPTB;Mz6xJI5ONXe1eHpnW0GQR1XS
CGTH-W-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXLTWM2OD1|LkGgcm0>M2jWNnNCVkeHUh?=
SK-PN-DWMn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLXZW52UUN3ME2zMlE1KG6PM4LHfnNCVkeHUh?=
CW-2MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkj2TWM2OD1|LkKxJI5ONX\ITXROW0GQR1XS
SK-N-DZNXe0[I8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPJZ5RKSzVyPUOuNlYhdk1?MUTTRW5ITVJ?
NEC8MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TocGlEPTB;Mz6zOUBvVQ>?NVS2WVc4W0GQR1XS
LB996-RCCM4C1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIqxTYNKSzVyPUOuOEBvVQ>?NXXydmdrW0GQR1XS
DBMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkX3TWM2OD1|LkSxJI5ONUTzd4p5W0GQR1XS
TE-15MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHz5cGhKSzVyPUOuOFMhdk1?MUDTRW5ITVJ?
COR-L88NUGxRlJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XY[2lEPTB;Mz60O{BvVQ>?MYDTRW5ITVJ?
LAMA-84M1\pfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTNwNEmgcm0>MXLTRW5ITVJ?
MEG-01NVTRWFlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fDeWlEPTB;Mz60PUBvVQ>?NXz3U2gzW0GQR1XS
LOXIMVINHz6[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PlXWlEPTB;Mz61JI5OMVnTRW5ITVJ?
RPMI-8402M2Hscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDrdoFoUUN3ME2zMlUhdk1?NGfNWXNUSU6JRWK=
KARPAS-45M2PZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHsdnpDUUN3ME2zMlU1KG6PNFiwVWhUSU6JRWK=
HCC1187MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEn3[IFKSzVyPUOuOVQhdk1?NELZTZlUSU6JRWK=
MZ1-PCM3izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\JTWM2OD1|LkW0JI5OMkO5V2FPT0WU
no-11Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HXT2lEPTB;Mz61OUBvVQ>?M4TINnNCVkeHUh?=
EVSA-TMoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTNwNjDuUS=>Ml7LV2FPT0WU
DJM-1NWPGWGJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfpZ49KSzVyPUOuOlMhdk1?M2PCfnNCVkeHUh?=
COLO-684NWnSNJkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHsTWM2OD1|Lk[2JI5OMnPkV2FPT0WU
NMC-G1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvqTWM2OD1|Lk[4JI5ONGS0eY9USU6JRWK=
LC-1FMlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\je2lEPTB;Mz63OEBvVQ>?Ml3HV2FPT0WU
RL95-2NYKxO3poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHMWlBKSzVyPUOuO|khdk1?NIXIe2hUSU6JRWK=
COLO-320-HSRNFjHR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\Ud5d6UUN3ME2zMlkzKG6PNIDlR|JUSU6JRWK=
RCC10RGBMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{e5b2lEPTB;Mz65N{BvVQ>?NYPGc49SW0GQR1XS
HD-MY-ZMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTNwOUOgcm0>MVPTRW5ITVJ?
NCI-H2141M3\VZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTRwMEWgcm0>MoXEV2FPT0WU
K-562MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;VWpNKSzVyPUSuNVIhdk1?M1PuR3NCVkeHUh?=
NCI-H1648NFTxVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorUTWM2OD12LkGzJI5OMlfmV2FPT0WU
OMC-1NHTGXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moi2TWM2OD12LkG4JI5OMVzTRW5ITVJ?
LB647-SCLCMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jqOmlEPTB;ND6yNkBvVQ>?Mk\rV2FPT0WU
TE-12M2DE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nkZ2lEPTB;ND6yOUBvVQ>?M2LXdnNCVkeHUh?=
NOMO-1M{TNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\Lb2lEPTB;ND6zN{BvVQ>?MkK4V2FPT0WU
RajiM4TGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEKwT3NKSzVyPUSuOFYhdk1?NXnFVo9rW0GQR1XS
NALM-6NHfmcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYP6[pZPUUN3ME20MlQ6KG6PNGHTfmtUSU6JRWK=
HL-60MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XvSmlEPTB;ND62O{BvVQ>?NES0O|FUSU6JRWK=
IST-SL1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HYc2lEPTB;ND62PEBvVQ>?MW\TRW5ITVJ?
MHH-PREB-1NES4fIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M323VmlEPTB;ND64OkBvVQ>?NGT1[4VUSU6JRWK=
MHH-NB-11MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHQTWM2OD12LkmxJI5OMV\TRW5ITVJ?
JiyoyeP-2003Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTVibl2=MmLrV2FPT0WU
SBC-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTVwMEGgcm0>MYXTRW5ITVJ?
CHP-126MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTVwME[gcm0>NETJUYJUSU6JRWK=
LU-139NEi3To5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTVwMUOgcm0>NYG3[IZPW0GQR1XS
NCI-SNU-5NWPmOpNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUexeYM{UUN3ME21MlE4KG6PMmfiV2FPT0WU
SW962MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnv4TWM2OD13LkKxJI5ONX7DZY43W0GQR1XS
EW-1M4DLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLkdJVJUUN3ME21MlMyKG6PNV30[|BKW0GQR1XS
NCI-H1417M3[w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzMbllKSzVyPUWuOVEhdk1?MUTTRW5ITVJ?
LU-65M4LEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTVwOESgcm0>NFj6XmNUSU6JRWK=
D-502MGMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;USJRXUUN3ME22MlM4KG6PMXLTRW5ITVJ?
BC-3NWfHR5RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXvUZZKUUN3ME22MlYyKG6PNEHabXpUSU6JRWK=
GDM-1NXTsbJlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTZwN{egcm0>NX36UItvW0GQR1XS
NCI-H2196NH3YTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zoe2lEPTB;Nj64JI5OMlLsV2FPT0WU
NB1NWjaR2Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnjXXB6UUN3ME22Mlg5KG6PMmLaV2FPT0WU
NCI-H345MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljNTWM2OD15LkKgcm0>MYrTRW5ITVJ?
SU-DHL-1M3\we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHWzXZBKSzVyPUeuNlQhdk1?NHyyN5NUSU6JRWK=
JVM-2MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTdwMkigcm0>NWq0[Wd[W0GQR1XS
LU-134-AMl;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTdwM{mgcm0>MXfTRW5ITVJ?
NCI-H1694MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjDZ5hKSzVyPUeuOVghdk1?NXG3SohrW0GQR1XS
NCI-SNU-16NGDRT|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGWyWodKSzVyPUeuOlUhdk1?Mn\jV2FPT0WU
L-363MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fm[WlEPTB;Nz63JI5OM2DsUnNCVkeHUh?=
KG-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTdwOUSgcm0>MnXYV2FPT0WU
MN-60NF;MXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITjWZJKSzVyPUiuNVQhdk1?NG\HVohUSU6JRWK=
NB6NVv1THVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPwTWM2OD16LkS4JI5OMkWyV2FPT0WU
MLMANULicYV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfoTWM2OD16Lki1JI5ONV2wPVl2W0GQR1XS
ATN-1NILQV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPjTWM2OD16Lki5JI5OMmDqV2FPT0WU
SK-NEP-1NEDEW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\zTWM2OD17LkCxJI5OMVvTRW5ITVJ?
DMS-114MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDhVpRMUUN3ME25MlYzKG6PMlnXV2FPT0WU
CTB-1NGnST|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4H3WmlEPTB;OT62O{BvVQ>?NHLPOY1USU6JRWK=
NCI-H2081MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjZSWRTUUN3ME2xNE4xQSCwTR?=M3jUOXNCVkeHUh?=
ES5M2fVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvHTWM2OD1zMD6zPEBvVQ>?MlHZV2FPT0WU
HCC1599NELSb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTFzLkmxJI5OM1:5U3NCVkeHUh?=
NCI-H23NUHU[Yx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTF{LkGyJI5OMl70V2FPT0WU
NCI-H1581NIrxNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\uV5N{UUN3ME2xNk4zQCCwTR?=MVrTRW5ITVJ?
JVM-3NETYT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\GTWM2OD1zMj65PUBvVQ>?MVrTRW5ITVJ?
NCI-SNU-1MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTF|LkG5JI5ONGn6bmZUSU6JRWK=
NB7MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLsdG5KSzVyPUG1MlkzKG6PNESzNZJUSU6JRWK=
JARMoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzoUndFUUN3ME2xOk4yOyCwTR?=NEL6UWdUSU6JRWK=
TGWNFLhWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVSycJpCUUN3ME2xOk41QCCwTR?=M{jK[XNCVkeHUh?=
U-87-MGMkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvISYdKSzVyPUG2Mlc3KG6PM{LsOHNCVkeHUh?=
NCI-H1436NXL1epZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{n5SGlEPTB;MUeuNFEhdk1?M1Ww[3NCVkeHUh?=
GOTOMmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXDTWM2OD1zNz6wOkBvVQ>?NGXDOFFUSU6JRWK=
COLO-800Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jMW2lEPTB;MUeuOlQhdk1?NHnrd4tUSU6JRWK=
MFM-223MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGH5fWtKSzVyPUG3MlkyKG6PMV7TRW5ITVJ?
EW-18MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHnSFRVUUN3ME2xO{46PiCwTR?=NXnCS|V1W0GQR1XS
NB14NHLYOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn75TWM2OD1zNz65PEBvVQ>?MlTDV2FPT0WU
EB2MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzITWM2OD1zOD6wPEBvVQ>?NX7DNIw1W0GQR1XS
EoL-1-M4CxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfJSJpNUUN3ME2xPE4{OSCwTR?=NXS3ZnFpW0GQR1XS
NCCITMmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXWTWM2OD1zOD6zOkBvVQ>?NITwe|NUSU6JRWK=
DG-75M3u0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHLSXNKSzVyPUG4MlYyKG6PNYW5N|RGW0GQR1XS
HCC2218NVHVRY1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTF7LkWgcm0>MWfTRW5ITVJ?
TE-6NF[1eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTJyLkC4JI5ONHW3TIJUSU6JRWK=
SF539M3vqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLGTWM2OD1{MD62O{BvVQ>?Moj3V2FPT0WU
NCI-H446MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXqTWM2OD1{MT6xPEBvVQ>?M{fidHNCVkeHUh?=
IST-MES1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTJ{Lke3JI5OMW\TRW5ITVJ?
NCI-H82MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnhfW1MUUN3ME2yN{4xOiCwTR?=NEXuc|RUSU6JRWK=
HCC2157NH\IOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWn6SWRiUUN3ME2yN{4yOyCwTR?=M17qeXNCVkeHUh?=
EW-12NWTzb4lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTJ|LkG3JI5OM1HxbHNCVkeHUh?=
SIMAMmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XGUWlEPTB;MkOuN|ghdk1?M2T5eXNCVkeHUh?=
DOHH-2NY\icYxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPGVFdKSzVyPUKzMlQ2KG6PMo\WV2FPT0WU
IM-9NEmzeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fSN2lEPTB;MkOuOVQhdk1?MXnTRW5ITVJ?
EC-GI-10NHLEU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTJ2LkKzJI5OMkfYV2FPT0WU
HDLM-2M4PQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\BN3I1UUN3ME2yOE42PCCwTR?=M1\Kc3NCVkeHUh?=
LS-1034MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTJ3Lke1JI5OMWrTRW5ITVJ?
REHMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvpSVR6UUN3ME2yOk41OSCwTR?=MlHFV2FPT0WU
LU-165MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTJ4LkeyJI5ONV62N3dLW0GQR1XS
NH-12MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEX1eW5KSzVyPUK3MlY4KG6PMXrTRW5ITVJ?
WSU-NHLMkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{W1ZWlEPTB;MkiuN|khdk1?MlP6V2FPT0WU
ECC4M4Xmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDZToVrUUN3ME2yPE44QSCwTR?=NHTSeHFUSU6JRWK=
OCI-AML2MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1uyc2lEPTB;MkmuOlkhdk1?MnmxV2FPT0WU
EW-3NXHJV|VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PkZmlEPTB;M{CuOVkhdk1?NU\aVYY6W0GQR1XS
NCI-H526MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTN{LkW0JI5OMV3TRW5ITVJ?
NCI-H719NHWx[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF:yNYZKSzVyPUO0MlMyKG6PNVuwO2dKW0GQR1XS
KARPAS-422MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLIdXVmUUN3ME2zOU4xPCCwTR?=NHLxbpRUSU6JRWK=
SK-MEL-1M4HHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\H[2lEPTB;M{WuNVchdk1?Ml23V2FPT0WU
ES3NX3pNotiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTN3LkG5JI5OMmm0V2FPT0WU
UACC-812NFeyWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnjbnExUUN3ME2zOU41PCCwTR?=M1zYeHNCVkeHUh?=
C8166M4CxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDoc2pKSzVyPUO1Mlchdk1?NWT2WGZCW0GQR1XS
MDA-MB-134-VIM3;6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkCzTWM2OD1|NT64O{BvVQ>?NHXFZ4VUSU6JRWK=
D-283MEDNXTDd3B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjSR4ZKSzVyPUO3Mlc6KG6PNWPF[VRXW0GQR1XS
SHP-77M1nv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPCNZdKSzVyPUO4MlA{KG6PNIWw[mJUSU6JRWK=
NCI-H2227MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoX1TWM2OD12MD60PUBvVQ>?MXPTRW5ITVJ?
SKM-1M{TadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7nd5lYUUN3ME20Nk43OyCwTR?=NEDST|JUSU6JRWK=
L-428NH3YNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTR|Lki2JI5ONXzBUGNZW0GQR1XS
RPMI-6666MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;JSYFbUUN3ME20OU45QSCwTR?=MX7TRW5ITVJ?
NCI-H716MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1z6WWlEPTB;NEiuPFEhdk1?NEmwOoFUSU6JRWK=
DMS-79NX\YWWRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTVyLkexJI5OMWfTRW5ITVJ?
RS4-11MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1KwfGlEPTB;NUCuPFghdk1?MWDTRW5ITVJ?
NCI-H720NH7QSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTVzLkGxJI5ONVvBOIxXW0GQR1XS
MC-CARNILGeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4X3TmlEPTB;NUGuOVIhdk1?MkK1V2FPT0WU
TALL-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PlZmlEPTB;NUOuPVEhdk1?M1Xlb3NCVkeHUh?=
NCI-N87M1HYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTV2LkG4JI5ONFnHR5pUSU6JRWK=
P30-OHKNVvTfFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\FPXBKUUN3ME21OE43OSCwTR?=NH;VWXBUSU6JRWK=
LP-1NUfmbpBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkX4TWM2OD14MT6yPEBvVQ>?NUDEXoJsW0GQR1XS
YTMonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULjOZhnUUN3ME22NU45KG6PMnPMV2FPT0WU
MRK-nu-1Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILtTZlKSzVyPU[xMlgzKG6PMUTTRW5ITVJ?
BT-474M2G0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXmTWM2OD14NTDuUS=>NVfQWZVvW0GQR1XS
NCI-H322MNXXSOI1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3obnpKSzVyPU[2MlEyKG6PM2\JbHNCVkeHUh?=
NCI-H128NEP1ZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXPcnpKSzVyPUe0Mlc4KG6PMWrTRW5ITVJ?
KMS-12-PEM4nSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTZTWM2OD15Nj6yOEBvVQ>?M2\HXXNCVkeHUh?=
KP-N-YSNFzQWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3VTWM2OD15Nj63OEBvVQ>?MWLTRW5ITVJ?
ALL-POM1vIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzCTWM2OD15Nz62OkBvVQ>?MmHkV2FPT0WU
EW-13Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTd5Lke2JI5OM4nVWnNCVkeHUh?=
EW-11NInBOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;DU2lEPTB;N{iuOVIhdk1?M2H1R3NCVkeHUh?=
SK-N-FING\6bHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjaeYVKSzVyPUiwMlIhdk1?MWjTRW5ITVJ?
CAL-148NF;XcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LxdmlEPTB;OEGuPFQhdk1?NH7JV2tUSU6JRWK=
RLMkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG[0No9KSzVyPUi2MlA6KG6PNUPuOWdvW0GQR1XS
AM-38M3HGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTh6LkC4JI5ONUDveYpuW0GQR1XS
RH-1M3GzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLKTWM2OD17OT64OUBvVQ>?MYfTRW5ITVJ?
NCI-H1770MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIX6Vm5KSzVyPUGwNk41QSCwTR?=NFnNUopUSU6JRWK=
SIG-M5Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;ITWM2OD1zMEWuNFYhdk1?NI\ybolUSU6JRWK=
GR-STMkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HRW2lEPTB;MUGzMlM1KG6PNFK0OoVUSU6JRWK=
ST486MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTFzND6wOkBvVQ>?NH\IR3FUSU6JRWK=
NCI-H1650MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTMTWM2OD1zMUWuNlkhdk1?NF;JOIZUSU6JRWK=
MHH-CALL-2NVXEbpQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITHXFJKSzVyPUGxOU44KG6PNHrVWnBUSU6JRWK=
BV-173M2fKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXP2ZmdiUUN3ME2xNlIvPzFibl2=NXHzZmdJW0GQR1XS
MC116NY\F[HBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfuPJBKSzVyPUG0PE45PSCwTR?=NY\NSGZ6W0GQR1XS
NCI-H524MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nsXGlEPTB;MUW5MlEhdk1?MXfTRW5ITVJ?
SCLC-21HMkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIf6PXBKSzVyPUG1PU41OSCwTR?=M2XrNnNCVkeHUh?=
NCI-H1304MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTF4OT6yNUBvVQ>?M37SdXNCVkeHUh?=
NCI-H510AM4XkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTF6NT6zO{BvVQ>?NXHqbIZyW0GQR1XS
NCI-H209MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjnTWM2OD1zOU[uOVIhdk1?MX3TRW5ITVJ?
KM-H2MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrMWpJHUUN3ME2xPVcvODVibl2=MYDTRW5ITVJ?
NCI-H1395M3;0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTUTWM2OD1{MUCuNVMhdk1?MV7TRW5ITVJ?
NCI-H1155NWfObGJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLFTWM2OD1{M{CuN|Ihdk1?MXPTRW5ITVJ?
COR-L279M36zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PtcWlEPTB;MkWyMlE4KG6PMVvTRW5ITVJ?
NCI-H1299MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PMdGlEPTB;Mk[xMlcyKG6PMYLTRW5ITVJ?
EW-22M4DyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGm3TFBKSzVyPUK2N{44PSCwTR?=MkW5V2FPT0WU
SK-MEL-2MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjGTWM2OD1{OEGuPUBvVQ>?MWfTRW5ITVJ?
KASUMI-1M173bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTkXIROUUN3ME2yPFMvODVibl2=NX;uOJg6W0GQR1XS
NCI-H187MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTwTWM2OD1{OEeuNFghdk1?M2DHZ3NCVkeHUh?=
NCI-H2171MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLhb3hKSzVyPUK4PE46OiCwTR?=MlzDV2FPT0WU
LNCaP-Clone-FGCM1\TUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTJ7NT6yOkBvVQ>?MnnqV2FPT0WU
NCI-H1522NH3uT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknrTWM2OD1|MEeuNFUhdk1?MVvTRW5ITVJ?
SCHNIP5VlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVG1TYtQUUN3ME2zNlIvOjJibl2=NVPheIVWW0GQR1XS
THP-1NGPX[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWL6cGpIUUN3ME2zNlIvPiCwTR?=MYXTRW5ITVJ?
SNU-C1NWHlXpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULHS4NQUUN3ME2zOlIvODlibl2=MVjTRW5ITVJ?
CA46NF7VT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTN5Mz62N{BvVQ>?NE\XW5pUSU6JRWK=
NCI-H1963NUPpVW9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkizTWM2OD1|OE[uNVkhdk1?MVnTRW5ITVJ?
DELMlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1u0UWlEPTB;M{mxMlI4KG6PNHLlTVJUSU6JRWK=
TURMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWH1fZBnUUN3ME2zPVYvPjFibl2=M1G1bHNCVkeHUh?=
NCI-H226Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvwZlBDUUN3ME20NFMvOjNibl2=Mnr5V2FPT0WU
COLO-668MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7q[XVKSzVyPUSwN{42PyCwTR?=M1n3[HNCVkeHUh?=
CPC-NMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTRyMz63O{BvVQ>?NEHPTJpUSU6JRWK=
NCI-H889MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTQTWM2OD12NkGuPVIhdk1?MYnTRW5ITVJ?
J-RT3-T3-5NHnoWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXS2c2V5UUN3ME21N|IvPTdibl2=MX7TRW5ITVJ?
MSTO-211HM1y4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFX4WotKSzVyPUW3OE4zPiCwTR?=M3;vNnNCVkeHUh?=
SCC-15MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfEbIhIUUN3ME22OlcvPDdibl2=M2rIU3NCVkeHUh?=
SUP-T1M2rQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX0d|lQUUN3ME22PFYvODRibl2=MYrTRW5ITVJ?
DMS-153MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTd2Nj64N{BvVQ>?M4W2b3NCVkeHUh?=
MS-1NYDW[|lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\Jc2lEPTB;N{W5MlQzKG6PNFzEdFJUSU6JRWK=
TC-YIKMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jIbWlEPTB;N{ixMlAyKG6PM2SxXnNCVkeHUh?=
RPMI-8866M3fzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1G2OGlEPTB;MUCwOk4zQCEQvF2=M{T6enNCVkeHUh?=
KY821NFXTR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;6TWM2OD1zMEO2MlA1KM7:TR?=MoC3V2FPT0WU
P31-FUJMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTFzMUKuO|Uh|ryPNV3FXYg6W0GQR1XS
COLO-824NV60VFFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDKb4NHUUN3ME2xNlYyNjd6IN88US=>MlHHV2FPT0WU
U-698-MMljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTJ{NkKuNVUh|ryPM4XQSXNCVkeHUh?=
TE-441-TMnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTJ3MkGuO{DPxE1?Ml3kV2FPT0WU
IMR-5NFPyb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXP0cYFqUUN3ME2zOFA6NjZ{IN88US=>MXnTRW5ITVJ?
NCI-H1838NWTUUW1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjHPGxKSzVyPUSxPFYvOzJizszNNGqw[lZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[4]

Kinetic Methods In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.

Cell Assay:

[5]

Cell lines Human multiple myeloma cells line U266
Concentrations ~10 μM
Incubation Time 2 days
Method

The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.

Animal Study:

[3]

Animal Models Human plasmacytoma xenografts RPMI 8226
Formulation Saline
Dosages 1 mg/kg
Administration i.v. twice weekly for 4 weeks, then once weekly

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Adams J, et al. Cancer Res, 1999, 59(11), 2615-2622.

[2] Boccadoro M, et al. Cancer Cell Int, 2005, 5(1):18.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-18)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02755597 Not yet recruiting Relapsed/Refractory Multiple Myeloma AbbVie|Genentech, Inc. June 2016 Phase 3
NCT02719613 Not yet recruiting Multiple Myeloma Bristol-Myers Squibb|AbbVie June 2016 Phase 2
NCT02783625 Recruiting Lymphoma|Relapsed/Refractory T-cell Lymphomas Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer  ...more Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Stanford University May 2016 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 2016 Phase 2
NCT02718833 Not yet recruiting Multiple Myeloma Massachusetts General Hospital|Celgene|Bristol-Myers Squibb March 2016 Phase 2

view more

Chemical Information

Download Bortezomib (PS-341) SDF
Molecular Weight (MW) 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LDP-341, MLM341
Solubility (25°C) * In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name B-​[(1R)​-​3-​methyl-​1-​[[(2S)​-​1-​oxo-​3-​phenyl-​2-​[(2-​pyrazinylcarbonyl)​amino]​propyl]​amino]​butyl]​-boronic acid

Customer Product Validation(20)


Click to enlarge
Rating
Source Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck
Method Western blots
Cell Lines Primary myoblasts
Concentrations 10, 50 uM
Incubation Time 24 h
Results To demonstrate the biological functionality of the salvaged missense mutated dysferlin protein, we performed membrane resealing experiments on primary myoblasts derived from percutaneous muscle biopsies taken from patient 2. Bortezomib treatment of primary myoblasts increased dysferlin expression in a dose-dependent manner, and bortezomib-treated myoblasts regained their capability to reseal laser-induced plasma membrane injuries.

Click to enlarge
Rating
Source J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck
Method Fluorescence
Cell Lines Primary myoblasts
Concentrations 2 mg/kg
Incubation Time 2 weeks
Results To examine this further, it determined whether inhibition of the proteasome with bortezomib blocked proplatelet formation in murine megakaryocytes. Similar responses were observed in human megakaryocytes, and removal of bortezomib from the incubation media restored proplatelet formation.

Click to enlarge
Rating
Source J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines Mouse primary osteoblasts
Concentrations 25 nM
Incubation Time 2 h
Results In support of this idea, the PTH-induced decrease of HDAC4 accumulation in osteoblasts was prevented by the addition of an inhibitor of proteasomal degradation, bortezomib.

Click to enlarge
Rating
Source Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck
Method H&E staining, Western blots, TUNEL assays
Cell Lines Foxp3flox/yxPBCre4+ mice
Concentrations 1 mg/kg
Incubation Time 60 weeks
Results Reduced cell proliferation was also observed in prostate epithelial cells of bortezomib-treated mice by Ki67 staining analysis (A). Furthermore, lack of nuclear p65 was observed in the bortezomib-treated prostate at 12 hours after LPS injection (B). To verify the impact of bortezomib treatment on NF-kB activation, we observed the expression of NF-kB targets in the mouse prostate. In contrast to the prostate-specific expression in untreated Foxp3cKO mice, the expression levels of Bcl2l1 and Traf1/2 were significantly downregulated in the prostates of treated mice (C). Importantly, the percentage of apoptotic prostate epithelial cells increased after bortezomib treatment (D).

Click to enlarge
Rating
Source Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence microscopy
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 45 min
Results Bortezomib and NH4Cl also increased the adjacency of DRIPs to SGs.

Click to enlarge
Rating
Source Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines wild-type oocytes, Fmn2-/-oocytes
Concentrations 0.1 μM
Incubation Time 90 min
Results Endogenous Fmn2, localized in the cortex of prophase I oocytes, disappeared at NEBD, reappeared later and was enriched in the cortex opposite the spindle. Fmn2 -/-oocytes lacked cortical Fmn2 staining, suggesting that the staining is specific. Cortical localization was maintained at NEBD in wild-type oocytes treated with the proteasome inhibitor, Bortezomib, indicating that Fmn2 is degraded at NEBD.

Click to enlarge
Rating
Source Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence Analysis
Cell Lines RS4;11cells
Concentrations 2.5 nM
Incubation Time 22 h
Results In RS4;11 samples combined treatment induces Ser536 p-NF-κB nuclear translocation (see white arrows).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Bortezomib and other inhibitors tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Bortezomib, Lapatinib, and LY294002 significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells.

Click to enlarge
Rating
Source J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck
Method Real Time PCR
Cell Lines HepAD38 cells
Concentrations 2-50 nM
Incubation Time 18 h
Results An inhibitory effect of proteasome inhibition by bortezomib on HBV replication can be observed in cell culture.Therefore, proteasome activation seems to be a valuable strategy of the infected cells to reduce the stress resulting from misfolded proteins.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines MA104 cells
Concentrations 0.1-10 μM
Incubation Time 1/7 h
Results Proteasome inhibitors which have different inhibition mechanisms, such as bortezomib and lactacystin, had a strong effect on virus replication in parallel with an increase in p53 accumulation.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines MA104 cells
Concentrations 10 μM
Incubation Time 5-10 h
Results Further kinetic experiments were performed to better define the time window within the viral replication cycle in which proteasome activity was required. For this, cells were infected for 1 h and treated with MG132 or bortezomib for 4h at different times postinfection (Fig. A). As shown in Fig. B, a more clear arrest on viral protein accumulation was observed when bortezomib or MG132 was added at relatively earlier time points. Indeed, when inhibitors were added at 5 h p.i. or later, the effect was much reduced, suggesting that once the infection was well established with a robust accumulation of viroplasms, the requirement for proteasome activity was less significant.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines NSP5-EGFP cells
Concentrations 10 μM
Incubation Time 2-8 h
Results Both MG132 and bortezomib induced a significant arrest on the formation of viroplasms, which appeared in reduced number and with smaller size with respect to those in control cells, particularly when added at time points between 1 h and 5 h p.i.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Quantification of viroplasms
Cell Lines NSP5-EGFP cells, MA104 cells
Concentrations 10 μM
Incubation Time 4 h
Results The number of viroplasms per cell in cells treated for 4 h with MG132 or bortezomib was almost the same as that found in cells fixed at the beginning of each treatment, strongly suggesting that inhibition of proteasome activity affected the assembly of new viroplasms and their growth.

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Proteasome activity assay, Standard plaque assay
Cell Lines A549 cells
Concentrations 10-100 nM
Incubation Time 1 h
Results As expected bortezomib treatment resulted in a block of viral replication of the avian influenzavirus strain A/FPV/Bratislava/79 (H7N7; FPV) in a concentration-dependent manner. While concentrations of 10 nM had no antiviral effect, 50 nM led to a significant titer reduction of up to 3 orders of magnitude (Fig.A). The highest concentration used (100 nM) led to a titer reduction of up to 4 orders of magnitude.These results were also confirmed in a virus growth kinetics study in infected cells that received a single dose of 50nM bortezomib. Virus titers were reduced at every time point analyzed (Fig.C).Since bortezomib is a proteasome inhibitor, we investigated whether the antiviral concentrations of bortezomib may have an inhibitory effect on the 26S proteasome in A549 cells. A concentration-dependent inhibition of the proteasome was observed in FPV-infected A549 cells at 24 h p.i. (Fig. B).

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Standard plaque assay, Western blot
Cell Lines A549 cells
Concentrations 50 nM
Incubation Time 1-10 h
Results A strong antiviral activity of bortezomib was observed upon addition of the compound up to 2 h p.i. At time points of 4 h p.i. and later, a dramatic decrease in the antiviral efficacy was observed. This indicates that the event in the viral life cycle that is affected by bortezomib occurs within the first 4 h. Since this correlates with the strong onset of viral gene and protein expression, we analyzed whether viral protein accumu-lation is affected by bortezomib. Indeed, we observed a strong reduction in viral matrix protein (M1) and PB1 polymerase synthesis in FPV- and PR8-infected cells at 5 h and 8 h p.i.

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines A549 cells
Concentrations 50 nM
Incubation Time 1/6/24 h
Results After a 6-h treatment with 50 nM bortezomib, activation of JNK was detected as evidenced by phosphorylation of the kinase at Thr183 and Tyr185 (lane 4). This was even enhanced upon a 24-h treatment (lane 6). Downstream substrates of JNK are the AP-1 transcription factors c-Jun and ATF-2, which are activated by JNK-mediated phosphorylation at Ser63 and Thr71, respectively. Consistent with JNK activation, we also found c-Jun and ATF-2 were phosphorylated and activated( lane 6), leading to the conclusion that, besides NF-κB, the JNK/c-Jun/ATF-2 pathway is also activated in A549 upon bortezomib treatment.

Click to enlarge
Rating
Source PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 50 μM
Incubation Time 4 h
Results Upon proteasome inhibition by Bortezomib an increased amount of around 5-6 fold of biotinylated molecules was detected, both in the absence and presence of US2 and US11.

Click to enlarge
Rating
Source 2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck
Method Western Blotting
Cell Lines KKU-M213 cells
Concentrations 0/20/40 nM
Incubation Time 0-12 h
Results We checked the effects of BTZ on the NF-κB pathway in KKU-M213 (Fig. a, b). BTZ induced IκB phosphorylation in dose- and time-dependent manners (Fig. a). Interestingly, reduced IκB was observed over time until it was barely detectable 12 h after treatment; as a result, nuclear NF-κB (p65) was markedly increased (Fig. b).

Click to enlarge
Rating
Source Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck
Method PB assay
Cell Lines S2-013
Concentrations
Incubation Time 24 h
Results It is noticed more deleterious effects by free bortezomib than by BTZ CS/GA nanoparticles.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) ic50 | Bortezomib (PS-341) price | Bortezomib (PS-341) cost | Bortezomib (PS-341) solubility dmso | Bortezomib (PS-341) purchase | Bortezomib (PS-341) manufacturer | Bortezomib (PS-341) research buy | Bortezomib (PS-341) order | Bortezomib (PS-341) mouse | Bortezomib (PS-341) chemical structure | Bortezomib (PS-341) mw | Bortezomib (PS-341) molecular weight | Bortezomib (PS-341) datasheet | Bortezomib (PS-341) supplier | Bortezomib (PS-341) in vitro | Bortezomib (PS-341) cell line | Bortezomib (PS-341) concentration | Bortezomib (PS-341) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us